Amgen (AMGN) Change in Account Payables (2009 - 2026)

Amgen's Change in Account Payables history runs 18 years deep, the most recent figure standing at $571.0 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 14.89% year-over-year to $571.0 million; the TTM figure through Mar 2026 stood at $502.0 million (down 36.13% YoY), while the FY2025 annual figure was $428.0 million, up 37.18% from the prior year.
• Change in Account Payables was $571.0 million for Q1 2026 at Amgen, up from -$484.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $643.0 million in Q2 2024 to a low of -$484.0 million in Q4 2025.
• Historically, Change in Account Payables has averaged $62.5 million across 5 years, with a median of -$44.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables plunged 702.38% in 2023, then surged 2060.87% in 2025.
• A 5-year view of Change in Account Payables shows it stood at $296.0 million in 2022, then tumbled by 163.18% to -$187.0 million in 2023, then slipped by 24.06% to -$232.0 million in 2024, then plunged by 108.62% to -$484.0 million in 2025, then jumped by 217.98% to $571.0 million in 2026.
• The last three Change in Account Payables figures came in at $571.0 million (Q1 2026), -$484.0 million (Q4 2025), and -$174.0 million (Q3 2025), per Business Quant data.